Clinical trials
Invasive Breast Carcinoma clinical trials
Below are recruiting invasive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04144023RecruitingPhase 1
Vaccine before surgery for HER2-positive breast duct cancer in place
This Phase 1 study tests a vaccine (H2NVAC) given before surgery to help the body fight HER2-expressing ductal carcinoma in situ (DCIS) that has not been removed yet. Because it’s early-stage, the main goal is to check safety and learn how the treatment may work.
Jacksonville, FloridaAges 18 years+ - NCT05999396RecruitingPhase 1
Testing a new antibody for colorectal cancer
This trial tests a new drug called CC-3, which is a type of antibody designed to help your immune system attack colorectal cancer cells. It is for people whose cancer has spread and who have already tried several standard treatments.
Tübingen, Baden-WurttembergAges 18 years+ - NCT06336928Recruiting
Blood test validation for breast cancer diagnosis
This study is testing a new blood test (liquid biopsy) to see if it can accurately detect breast cancer or track remission. If you are a woman getting a mammogram, have an abnormal finding, were recently diagnosed, or are in remission after treatment, you may be able to join and help validate this test.
Los Angeles, CaliforniaAges 18 years+ - NCT06195709RecruitingPhase 3
Study of PET imaging and blood tests for ER+ HER2- metastatic breast cancer
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
BayonneAges 18 years+ - NCT03448926Recruiting
DCIS test registry to guide radiation and drug decisions
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Scottsdale, ArizonaAges 30–85 - NCT06686459Recruiting
AI-assisted single-session radiotherapy after breast-conserving surgery
This trial tests a new approach where all radiation is given in one session using AI guidance. It is for women who had breast-conserving surgery with lymph node removal and need radiation afterward.
GuangzhouAges 18–70 - NCT06725940Recruiting
PET scan to check treatment response in breast cancer
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
ShanghaiAges 18–65 - NCT06191133RecruitingPhase 1
Fenofibrate for cervical pre-cancer and cancer
This study tests whether a cholesterol-lowering drug called fenofibrate can help people with cervical pre-cancer or cancer. You take the drug before your scheduled surgery or chemoradiation, and doctors check if it reduces abnormal tissue or enhances treatment.
Cleveland, OhioAges 18 years+ - NCT05911958RecruitingPhase 2
Study drug before surgery for HER2-low, HR-positive breast cancer
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
Zhengzhou, HenanAges 18–70 - NCT04677816RecruitingPhase 2
Vitamin D for a better response to chemotherapy
This study tests whether taking high-dose vitamin D before and during chemotherapy helps eliminate more cancer before surgery in people with triple-negative breast cancer who are low in vitamin D.
Winston-Salem, North CarolinaAges 18 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06640881RecruitingPhase 2
Repeat breast-conserving surgery with partial reirradiation
This trial tests a new approach for women whose breast cancer has returned in the same breast after earlier surgery and radiation. Instead of removing the whole breast, doctors will remove only the tumor again and give a small, focused dose of radiation before surgery, aiming to preserve the breast.
AmsterdamAges 50 years+ - NCT06113016RecruitingPhase 2
Preventing frailty with fisetin and exercise in breast cancer survivors
This study tests whether adding a supplement called fisetin to an exercise program can help prevent frailty in women who have finished chemotherapy for early-stage breast cancer. If you are postmenopausal, have completed chemo within the last year, and can walk a certain distance, you may qualify.
Alhambra, CaliforniaAges Any age - NCT07260188Recruiting
Breast cancer organoids from patients before chemo
This study collects tumor tissue from breast cancer patients before they start chemotherapy to grow miniature versions of their tumors (organoids) in the lab. The goal is to understand how each tumor responds to treatment, which may help personalize future therapies.
Pavia, PVAges 18 years+ - NCT06026657RecruitingPhase 1/Phase 2
NK cells with or without naxitamab for GD2-positive breast cancer
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Columbus, OhioAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT05379153RecruitingPhase 3
Laser therapy for vaginal dryness in breast cancer survivors
This trial tests whether laser therapy can help women who have had breast cancer and now experience vaginal dryness. It aims to see if this treatment can reduce dryness and improve comfort.
Ann Arbor, MichiganAges 22 years+ - NCT06537960Recruiting
Later scan images to better see bladder cancer spread
This trial tests whether taking extra, later images during your standard FDG PET-CT scan can give doctors a better view of how far your muscle-invasive bladder cancer has spread. You may be eligible if you are 18 or older, have confirmed muscle-invasive bladder cancer, and are already getting this type of scan.
Suresnes, Île-de-France RegionAges 18 years+ - NCT05301881RecruitingPhase 2
Continuing current treatment after local treatment for limited cancer growth
This trial tests whether continuing your current therapy after getting local treatment (like surgery or radiation) for a small area of cancer growth is safe and effective. It may help you keep the same treatment longer before switching to a new one.
AlkmaarAges 18 years+ - NCT07478016Recruiting
Studying inflammation and social factors in breast cancer
This study looks at how inflammation and social factors (like stress or support) affect breast cancer patients before they start treatment. You may qualify if you are a woman, newly diagnosed, and have not yet had any cancer treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07762885RecruitingPhase 3
Comparing skipping radiation after surgery for early-stage DCIS
This trial compares skipping radiation therapy after breast-conserving surgery for low- or intermediate-risk ductal carcinoma in situ (DCIS) – a very early, non-invasive breast cancer. It aims to see if omitting radiation is as effective as standard treatment while reducing side effects.
ShanghaiAges 40 years+ - NCT07762924RecruitingPhase 2
Skipping radiation for younger women with low-risk DCIS
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
ShanghaiAges Up to 40 years - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Birmingham, AlabamaAges 18 years+ - NCT00437879Recruiting
Ultrasound and MRI scans to track breast cancer response early
This study uses ultrasound and/or MRI scans to see how breast cancer responds early while you start “neoadjuvant” treatment (chemotherapy, with or without radiation before surgery). It may help doctors spot response sooner and better understand which imaging changes match treatment benefit.
Toronto, OntarioAges Any age
Hear when a new Invasive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for invasive breast carcinoma?
- Yes. Clin2 currently lists 149 recruiting invasive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a invasive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a invasive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.